CD40 and neoplasm: Despite the ability of the combination therapy of PD-1 blockade and CD40 agonist to enhance Th1 cell presence in “cold” regions, the overall T cell activity remained suboptimal compared to “hot” regions, resulting in an inability to induce tumor rejection.259